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Abstract. Sickle pain is the hallmark of sickle cell disease (SCD). It could be acute, 
persistent/relapsing, chronic, or neuropathic. Although there is a general consensus that pain is a 
major manifestation of SCD, there is a controversy as to the types of pain and their 
interrelationship between acute, chronic, relapsing, persistent, etc. This report first reviews the 
general approach to the management of acute vaso-occlusive crisis (VOC) pain, including 
education, counseling, pharmacotherapy, non-pharmacotherapy, and fluid therapy. This is 
followed by the presentation of five patients that represent typical issues that are commonly 
encountered in the management of patients with SCD. These issues are: individualized treatment 
of pain, bilaterality of pain, use of illicit drugs, tolerance to opioids, opioid-induced hyperalgesia, 
and withdrawal syndrome. The clinical aspects and management of each of these issues are 
described. Moreover, such complications as tolerance and withdrawal may persist after discharge 
and may be mistaken as chronic pain rather than resolving, persistent or relapsing pain.  
  
Keywords: Sickle cell disease; Sickle cell anemia; Pain; Vaso-occlusive crisis. 
 
Citation: Ballas S.K. How I treat acute and persistent sickle cell pain. Mediterr J Hematol Infect Dis 2020, 12(1): e2020064, DOI: 
http://dx.doi.org/10.4084/MJHID.2020.064  
 
Published: September 1, 2020 Received: June 16, 2020 Accepted: August 13, 2020 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
 
Correspondence to: Samir K. Ballas MD FACP. Cardeza Foundation, Department of Medicine, Sidney Kimmel Medical College, 
Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107. Tel: 856 745 6380, Fax: 856 795 0809. E-Mail: 
Samir.ballas@jefferson.edu 
Introduction. The hallmark of sickle cell disease (SCD) 
is the recurrent acute painful vaso-occlusive crises 
(VOCs) and the persistent pain (PP) in between crises in 
about 50% of adults and 9% of children.1-3 These types 
of pain are unique to patients with SCD and punctuate 
the quality of their life with uncertainty, suffering, poor 
education, poverty, dysfunctional family life, and 
dependence on a fragile medical support system. The 
frequency, severity, location, and duration of both the 
VOCs and PP vary considerably among patients and 
longitudinally in the same patient. The reasons for these 
fluctuations are not well known.4 Moreover, most 
patients present with neither obvious precipitating 
factors nor objective signs.5-7 This state of affairs creates 
suspicion among some providers about the authenticity 
of the VOCs and the resulting accusations of 
maladaptive behavior.8 
The PP between crises has been labeled as chronic 
pain by some providers.1 By doing so, the uniqueness of 
sickle cell pain is undermined, and the patients with 
SCD are lumped with other chronic pain syndromes in 
the general population. This lumping rendered the PP 
subject to the rules, regulations, and guidelines for the 
treatment of chronic pain.9 Moreover, since patients 
with SCD use relatively frequent and large doses of 
opioids, they have been assumed to be associated with 
the opioid epidemic. Consequently, patients with SCD 
and pain became often unfairly undertreated with 
opioids. 
The purpose of this report is to describe patients with 
SCD who presented with different pain characteristics 
that were addressed and resolved in a manner based on 
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the changing reality of pain among patients over the 
dimensions of space and time.10 
 
Overview of Treatment 
Education and counseling.  Educating and 
counseling patients with SCD is a continuous process 
that starts when first seen and continues through future 
follow-ups. I explain the beneficial and harmful effects 
of prescribed medications, including opioids.  
Prescriptions are given as needed. Vaccines are 
administered when required.11 Patients, parents, and 
other family members are instructed on what to expect 
regarding sickle cell syndromes by making them aware 
of the signs and symptoms of VOCs, infection, acute 
chest syndrome (ACS), etc. The adoption of good health 
habits is reinforced, and the avoidance of situations and 
factors that could precipitate a VOC is emphasized.5,11 
This process of education and counseling results in a 
written consent form and individualized treatment plan 
with the patient or parents if long-term opioids are 
indicated.12 The agreement lists the patient's rights and 
responsibilities, and the treatment plan contains the type, 
amount, and route of administration of the opioid in 
question, including random drug urine testing. 
 
Pharmacotherapy of Pain. I use nonsteroidal anti-
inflammatory drugs (NSAIDs), short-acting opioids, 
and adjuvants to treat acute pain.13,14 The use of 
NSAIDS is limited to patients whose serum creatinine is 
≤ 1.0 mg/dL, and they have no proteinuria or 
albuminuria. The adjuvants include antihistamines, 
antiemetics, laxatives, antidepressants, and 
gabapintinoids as needed. I go over the personal side 
effects of opioids listed in Table 1. The use of opioids 
by patients with SCD is not as problematic as it is in the 
general population. A review of data from the Centers 
for Disease Control and Prevention (CDC) between 
1999 and 2013 showed that less than 1% of deaths 
among patients with SCD was due to opioid overdose, 
and this low rate of mortality did not change 
significantly over the 15-year data.15 
 
Fluid Therapy. I encourage my patients to use water for 
oral hydration and avoid soft drinks as often as possible. 
Signs and symptoms of dehydration include dry mouth, 
tongue, and lips, decreased skin turgor, flat neck veins, 
and serum creatinine level higher than steady-state 
values. I do not use normal saline for intravenous 
hydration but use 5% DW or other crystalloids. I 
monitor the status of hydration by determining daily 
fluid intake and output, daily weight, and check if edema 
develops.16-18 Overhydration, like over blood transfusion, 
could be fatal.19-21 
 
Beyond Pharmacotherapy. With the help of our social 
workers, we address the psychosocial factors that 
pertain to each patient and recommend solutions. We 
Table 1. Opioid Risks. 
1. Mild/Moderate Side Effects: 
• Sedation 
• Confusion 
• Nausea 
• Dizziness 
• Constipation 
 
2. Serious Medical Side Effects: 
• Gonadal suppression 
• Respiratory suppression 
• Sleep apnea 
• Dental complications 
 
3. Serious Neurological and Behavioral Side Effects: 
• Physical dependence 
• Withdrawal 
• Tolerance 
• Hyperalgesia 
• Addiction 
• Pseudo addiction 
• Abuse, misuse, diversion 
 
also recommend nonpharmacologic therapies such as 
meditation, yoga, massage, relaxation, tai chi, etc.22,23 
 
Neuropathophysiology of Pain. This was previously 
reported10 and summarized in Table 2 and Figure 1.24 
 
Table 2. Pathways of the Transmission of painful Stimuli. 
1. Peripheral nervous system 
– Peripheral nerves 
• Voltage gated sodium channels 
• Nav1.7 – Na v1.9 
• Dorsal root ganglion 
2. Central nervous system 
– Dorsal horn of the spinal cord 
• Voltage gated sodium channels 
• α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) 
– Voltage Gated Calcium Channels 
• N-methyl-D-aspartate (NMDA) Receptor 
• alpha2-delta (α2-δ) subunit 
– Opioid Receptors: µ, ĸ, δ 
3. Central Sensitization 
4. Glial Activation 
 
Patient 1:  A woman with Hb SC disease and VOC 
that went amiss. A 39-year old African American 
woman known to have hemoglobin (Hb) SC disease was 
admitted to the hospital with the diagnosis of VOC. The 
pain involved the left shoulder and the upper/lower back 
and was constant, sharp and throbbing in nature with an 
intensity score of 10 on a scale from 0 (no pain) to 10 
(most severe pain). Past medical history was significant 
for VOCs at a rate of 2-3 VOCs per year with no pain 
between VOCs, avascular necrosis (AVN) of the left 
humeral joint, pneumonia, urinary tract infection, and a 
remote history of allergy to morphine. In the emergency 
department (ED), she was given meperidine 125 mg 
intravenously (IV) every two hours. She did not achieve 
adequate pain relief after receiving 3 doses of 
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Figure 1. Pathways through which pain stimuli are transmitted from the periphery to the brain.  Nav1.7 - NaV1.9 are peripheral voltage-
gated sodium channels; DRG: Dorsal root ganglion; DH: Dorsal horn of the spinal cord; T: Thalamus; RF: Reticular formation; LS: Limbic 
system. Adapted from Semin Hematol 2001; 38(4):307-314. Used with permission. 
 
meperidine and, hence, was admitted to the hospital. The 
attending provider decided to start her on patient-
controlled analgesia (PCA) pump using morphine 
lockout dose 1 mg, lockout interval 10 minutes, and a 
one-hour dose limit of 8 mg morphine. The patient 
indicated that she is allergic to morphine and usually 
receives meperidine for pain, but she could not give 
details about the nature of the allergy to morphine. 
About 8 hours after starting the PCA, she experienced 
hallucinations, disorientation, fever 103 ͦ F, chest 
oppression, and difficulty breathing with pulse 
Oximetry of 86%. She was transferred to the intensive 
care unit and intubated. The chest x-ray was normal. She 
recovered within 24 hours, and management of pain was 
resumed with meperidine and was discharged 7 days 
after admission. 
 
Comments on patient 1. Management of patients with 
sickle cell pain should be individualized. Patients with 
SCD are authorities on their disease. They know what 
helps them most. Accordingly, providers should listen, 
believe, and respect patients unless proven otherwise. 
The selection of a specific opioid and its dose should be 
based on the patient's previous experience. No opioid or 
a specific dose of an opioid applies to all patients all the 
time. Opioids are ligands that bind to receptors and slow 
the transmission of painful stimuli along the central 
nervous system pathways. The binding to and activation 
of a specific receptor by an opioid vary considerably 
among patients. Opioid receptors are G protein-coupled 
with exogenous and endogenous opioids as ligands.25 
Recent studies25-27 have revealed a helical structure of 
the opioid receptors, which forms pockets in which the 
corresponding ligand (opioid) fits snugly. Not all 
opioids fit snugly into the same receptor's pocket. This 
explains why some patients may have better analgesia 
with a certain opioid but not with another opioid.  
 
Patient 2:  A man with SCA and urine drug screen 
positive for cannabis and phencyclidine. A 22 year-
old-African American man with sickle cell anemia 
(SCA) whose past medical history was significant for 
frequent VOCs that required hospitalizations > 5 times 
per year with intermittent pain between VOCs. Pain 
during crises was usually constant, sharp, and throbbing 
in nature with a score of 8-10/10 and involved the low 
back, right shoulder, knees, and legs. Complications of 
his disease included ACS, AVN of hips and right 
shoulder, priapism, and frequent blood transfusions. In 
addition, he had asthma as a child and heparin-induced 
thrombocytopenia. He refused to take hydroxyurea. 
Social history was positive for tobacco, cannabis, and 
alcohol use. Lab data in the steady-state included Hb 
that varied between 8 and 10 g/dL, Hb F 11%, 
reticulocyte count 10-15%, WBC count 8 – 14 B/L, 
normal platelet count, mildly elevated total bilirubin 
level and normal hepatic and renal parameters. Pain 
management included morphine and ketorolac during 
hospitalizations and oxycodone/ acetaminophen 
(Percocet) as an outpatient.   
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When first seen in our center, agreement, and consent 
forms that included random urine drug testing were 
discussed and signed by the patient and the provider. 
The first random urine drug testing done was positive 
for opiates and cannabinoids. Intensive counseling 
indicated that he smoked cannabis because Percocet did 
not give him adequate pain relief. The issue was 
resolved by replacing Percocet with morphine for the 
treatment of pain as an outpatient with the patient 
affirmation that he will discontinue using cannabis 
subject to confirmation by random urine drug testing. 
Indeed, random urine drug testing one year later was 
negative for cannabis and positive for the opiates 
(morphine) he was taking. Unfortunately, the random 
urine drug testing done later when he was 24 years old 
was positive for opiates and phencyclidine.  
Another round of counseling revealed that 
phencyclidine gave him much better pain relief than 
morphine used to do. Accordingly, pain management 
was modified to use methadone up to 60 mg orally/day 
instead of morphine and 5% lidocaine patches to apply 
over the most painful area for a maximum of 8 hours per 
day as needed. Electrocardiogram (EKG) before and 
after using methadone showed no prolongation of the 
QTC interval. Methadone was chosen because, like 
phencyclidine, it inhibits the N-methyl-D-aspartate 
(NMDA) channel but less severely. This approach 
resulted in the discontinuation of phencyclidine and 
repeating urine drug test at the age of 25 years and again 
at the age of 26 years when he was last seen was positive 
for opiates only and negative for cannabinoids and 
phencyclidine.  
 
Comment on patient 2. This patient is a typical example 
of opioid tolerance that leads to the use of illicit drugs.  
It is defined as reduced potency of the analgesic effect 
of an opioid after repeated administration or the need for 
higher doses to maintain the same result. It shifts the 
dose-response curve to the right (Figure 2A).28 The 
binding of an opioid to its receptor generates a series of 
reactions that could culminate in tolerance, as shown in 
Figure 3.29 
Recent studies in mice have shown that tolerance to 
morphine seems to be modulated by the gut-
microbiome-central nervous system interactions.30-32 
Management of opioid tolerance entails the use of 
NMDA inhibitors. Actually, the illicit phencyclidine 
used by this patient is a potent inhibitor of the NMDA 
(Figure 4) not only at the level of the spinal cord but in 
all other tissues and organs and, hence, could be lethal.33 
The NMDA channel is a complex structure.34 It is 
both a receptor and a calcium-gated channel.35,36 
Therapeutic inhibitors of NMDR include ketamine, 
clonidine, Lidocaine, dextromethorphan, nitrous oxide, 
zinc, and methadone.29,37,38 More recently, rosuvastatin, 
B vitamins, and inhibition of platelet-derived growth 
factor-β (PDGFR-β) have been shown to attenuate or 
 
Figure 2. Tolerance and hyperalgesia. Tolerance in A shows a 
higher dose of an opioid is required to achieve the desired pain relief. 
Hyperalgesia in B shows that prolonged administration of opioids 
results in a paradoxical increase in severe pain after minor stimuli. 
Adapted from Best Pract Res Clin Anaesthesiol 2007; 21:65-83. 
Used with permission. 
 
eliminate the development of tolerance to morphine in 
rats and mice.39-42 Donica et al. reported that combining 
imatinib with a previously ineffective dose of morphine 
led to complete pain relief in male Sprague-Dawley 
rats.42 In addition, imatinib was effective in treating 
sickle cell VOC in patients with chronic myeloid 
leukemia and SCA, probably by inhibiting PDGFR-
β.43,44 
 
Patient 3:  A woman with Hb SC and VOC after C-
section that became symmetrically bilateral. A 26-
year-old pregnant African American woman Hb SC 
disease had a Cesarean section (C-section) at week 37 
gestation due to signs of fetal distress with abnormal 
fetal heart tracing.  The surgery was uneventful, and the 
fetus survived with a normal APGAR score. Past 
medical history was significant for relatively infrequent 
VOCs (< 2 per year) and splenic sequestration during 
infancy that did not require splenectomy. During 
pregnancy, she took oxycodone 5 mg plus 
acetaminophen 325 mg (Percocet) prn for pain. The 
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Figure 3. The effect of short- and long-term opioid therapy on opioid-receptor signaling. (A) Binding of an opioid to cell membrane µ-receptors 
activates the receptor's G protein that dissociates into Gα and Gβγ subunits. These, in turn, inhibit voltage-gated calcium channels and activate 
potassium channels resulting in K+ loss causing membrane hyperpolarization and decreased transmission of painful stimuli and opioid-
analgesia. However, soon after the opioid binds to its receptor it is subject to phosphorylation by GRK (G-protein-coupled receptor kinase) 
culminating in the recruitment and binding of β-arrestin protein to the receptor. This results in desensitization of the receptor thus decreasing 
the response to the opioid inducing insufficient analgesia and tolerance. (B) Long term therapy with an opioid associated with sustained β-
arrestin binding to the receptor often leads to internalization and degradation of the receptor. This, in turn, initiates a series of reactions that 
culminate in the activation of the N-methyl-D-aspartate (NMDA) receptor which result in diminishing the analgesic effect, increasing tolerance 
and opioid-induced-hyperalgesia. From N Engl J Med 2019; 380:365-378. Used with permission. 
 
 
Figure 4. The effect of phencyclidine (PCP) on the N-methyl-D-
aspartate (NMDA) receptor. PCP acts as a noncompetitive 
antagonist at NMDA receptor. As long as it is bound it renders the 
NMDA receptor nonfunctional. From Breedlove S.M., Watson N.V. 
Behavioral Neuroscience, Eighth Edition. Oxford University Press 
New York, NY; 2018. Used with permission. 
 
newborn infant had no signs/symptoms of neonatal 
abstinence syndrome. She was advised not to breastfeed 
her baby. On the 4th post-operative day, she had a sudden 
onset of severe pain, swelling, and tenderness in her 
right ankle. She achieved partial relief with morphine, 6 
mg IV every 2 hours. About 24 hours later, she had the 
same severe "mirror image" pain in her left ankle. Some 
providers questioned the validity of the symmetrical 
pain in the left ankle due to the unlikely possibility of 
having vaso-occlusion in such a symmetrical pattern. 
Physical exam, however, revealed the presence of 
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similar swelling and tenderness over both ankles. Better 
pain relief was achieved by increasing the dose of 
morphine to 8 mg IV every 2 hours. She continued to 
improve gradually and was discharged with her infant 
ten days after admission. 
 
Comment on patient 3. This patient illustrates two 
important issues in SCD: postpartum breastfeeding and 
the pathophysiology of the incidence of symmetrical 
bilateral pain. 
Women with SCD who take opioids during 
pregnancy must not breastfeed their infants to prevent 
newborn withdrawal syndrome that could be fatal. 
Codeine used to be considered a safe opioid analgesic 
for pain during breastfeeding. This changed after a tragic 
case report that pertains to an infant who died at the age 
of 13 days from morphine poisoning; the source of 
morphine was the codeine that the mother was taking. 
Further studies showed that the mother was an ultra-
rapid metabolizer of codeine, due to duplication of the 
CYP2D6 enzyme that metabolized codeine into 
morphine.45,46 The recommendation changed, indicating 
that women, in general, must not take opioids during the 
breastfeeding period.  
Symmetrical bilaterality of pain, such as both hips, 
both knees, was common in more than 60% of patients 
enrolled in the PiSCES study 47 and was also reported by 
others.48 The ankles and feet were the most common 
locations of bilaterality. The pathophysiology of this 
bilaterality is not known. One possibility is that it is 
referred pain to a site different than the original site of 
pathology.49 Shunting of the blood away from the bone 
marrow, the steal syndrome, is another possibility.48 
Another explanation of bilaterality is that it is due to 
central sensitization at the level of the spinal cord, as 
described by Woolf 50 in rats. The convergence of nerve 
fibers from two different sites at the same level in the 
spinal cord is perceived as pain in both sites (Figure 
5).51 
Most recently,  bilaterality seems to be due to a 
phenomenon called "bioelectric injury mirroring".52 
This extends our knowledge about the electrophysiology 
of regenerative response and identifies a novel 
communication process via a long-range spread of 
injury signaling (Figure 6).52 
 
Patient 4: A woman with Hb S-β0-thalassemia whose 
pain worsened after increasing the dose of morphine. 
A 29-year-old African American woman with sickle -β0-
thalassemia was admitted to the hospital with VOC 
involving her low back, chest, and knees. The pain was 
typical of her VOCs and was constant and 
sharp/throbbing in nature with an intensity score of 
10/10. She also complained of fatigue, malaise, nausea, 
and vomiting.  
Past medical history was significant for frequent 
VOCs (≥ 5 per year) that required treatment in the ED 
 
Figure 5. Viscero-somatic convergence of primary afferent fibers 
on neurons of lamina I and lamina V of the dorsal horn. IML: 
intermediolateral cell column. From Lancet 1999; 353: 2145-2148. 
Used with permission. 
 
or in the hospital, cholecystectomy, splenectomy, ACS, 
repeated blood transfusions, iron overload, deep vein 
thrombosis, migraine headache, urinary tract infection, 
and C-section at 34 weeks gestation due to twin 
pregnancy with both babies in the breech position. 
Pain management in this admission included a 
morphine PCA pump with a basal rate of 4 mg/h and 1 
mg lockout every 10 minutes with a one-hour dose limit 
of 10 mg and ibuprofen. Emesis was controlled with 
ondansetron IV. Adjuvants included antihistamines and 
laxatives. She required two units of RBC transfusion to 
keep her Hb > 8g/dL. She was also given heparin for 
deep vein thrombosis prophylaxis. She continued to 
complain of severe pain that required increasing the 
dose limit of morphine to 16 mg/hour.  At the same time, 
the distribution and the descriptors of the pain changed; 
it became worst in her legs and deep burning in nature. 
Examination showed severe allodynia where a 
superficial touch of her legs caused severe pain, and she 
avoided covering her legs with the blanket to prevent 
pain. The diagnosis of morphine-induces hyperalgesia 
was made. The dose of morphine was gradually 
decreased and replaced with an equianalgesic dose of 
hydromorphone, up to 8 mg iv q2hour. Eventually, 
adequate relief was achieved with hydromorphone. She 
was discharged on the 24th hospital day on 
hydromorphone and ibuprofen. 
 
Comment on patient 4. This patient's pain is a typical 
example of opioid-induced hyperalgesia (OIH). It is 
defined as increased sensitivity to pain stimuli 
(hyperalgesia) and pain caused by ordinarily nonpainful 
stimuli (referred to as allodynia). Typically, 
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Figure 6. Frogs Have a Bioelectric Mirror. (A) Amputation of one limb triggers a rapid electric response that reflects the injury in the 
opposite not injured one. From Development 2018; 145: dev164210. (B) Depolarization patterns (brighter green) in the uninjured leg (bottom) 
occur within seconds of amputation of the opposing leg (top). From Tufts Now. Amputation injury is communicated to opposing limbs. Tufts 
Now; 2019. Used with permission. 
 
hyperalgesia is noted in parts of the body different from 
the site of the original pain complaint, and the 
descriptors of the pain change with some similarity to 
certain aspects of neuropathic pain such as burning 
sensation.  Unlike tolerance, OIH worsens with higher 
doses of opioids (Figure 2B).53-55 
The pathophysiology of OIH is not well understood. 
A proposed mechanism is the activation of the NMDA 
receptor.33,53 This activation results in calcium influx, 
which in turn enhances the excitability of neurons, 
which facilitates further transmission of painful 
stimuli.33 
Studies in rats showed that morphine hyperalgesia 
appears to be secondary to the activation of specific 
receptors within microglia since the ablation of the 
microglia prevented OIH.56 Figure 7 illustrates how glia 
interact with neurons and the surrounding blood 
vessels.57 
Management of OIH involves weaning from opioids, 
opioid rotation, and the use of NMDA inhibitors such as 
methadone, clonidine, Lidocaine, or ketamine as needed. 
Weaning and rotation are usually done together, as was 
described in this patient.  
 
Patient 5: A man with SCA and recurrent severe 
pain between VOCs. A 42-year-old African American 
man with SCA presented to the ED with severe diarrhea 
and nausea/vomiting of five-days duration. These signs 
and symptoms were associated with nasal congestion, 
rhinorrhea, cough, and severe crampy abdominal pain 
and a VOC with severe pain involving his low back, 
arms, and legs that brought him to the ED. Medications 
included Hydroxyurea 1500 mg/day and 
hydromorphone 4 mg by mouth q 2h as needed. 
Other complications of his SCA included a history of 
cholecystectomy, obstructive sleep apnea treated at 
home with oxygen, AVN of the right hip that required 
arthroplasty, and pneumonia. 
Physical exam included a temperature of 99.6°F, RR 
30/min heart rate 130/min, pulse oximetry 99% on 2 
 
  www.mjhid.org Mediterr J Hematol Infect Dis 2020; 12; e2020064                                                         Pag. 8 / 12 
 
 
 
Figure 7. Different types of glia interact with neurons and the surrounding blood vessels. Oligodendrocytes wrap myelin around axons to 
speed up neuronal transmission. Astrocytes extend processes that ensheath blood vessels and synapses. Microglia keep the brain under 
surveillance for damage or infection. From Nature 2009; 457: 675-677. Used with permission. 
 
liters oxygen. The patient was restless, anxious, and 
sweaty. Heart and lung exams were normal. A large 
ulcer over the left lateral ankle and a smaller ulcer over 
the right medial ankle were both clean and healing 
gradually. 
Lab data included Hb 7.7 g/dL, reticulocyte count 
7.9%, mean corpuscular volume (MCV) 120 fL, serum 
creatinine 1.0 mg/dL and normal serum electrolytes and 
liver function tests. A diagnosis of VOC precipitated by 
viral gastroenteritis was made and treated accordingly. 
Cultures of stools, urine, and blood were all negative. 
Chest X-ray and EKG were within normal. Treatment 
included hydration, opioid analgesia with 
hydromorphone up-to 8mg q 2h IV plus hydroxyzine as 
an adjuvant, antiemetics with ondansetron, and anti-
laxatives with loperamide. He improved gradually, and 
after 15 days of hospitalization, he was discharged on 
hydromorphone 4 mg by mouth q2h and acetaminophen 
325 mg/oxycodone 5 mg three times daily as needed.   
During the six months after this hospitalization, he 
was readmitted about once every month with similar 
signs and symptoms. The diagnosis was changed to 
gastroenteritis of unknown etiology. The home 
treatment of pain was changed up to 16 mg 
hydromorphone po every 2 hours. At this point, he was 
referred to our center for advice. 
A detailed review of the history and the physical 
exam revealed that the patient had adequate pain relief 
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with hydromorphone used at home for 3-4 days. After 
that, he gradually developed diarrhea, nausea/vomiting, 
running nose, abdominal cramps, followed by typical 
symptoms of VOC. This sequence of events recurred 
before the frequent hospital admissions mentioned 
above. This sequence of events was typical of 
withdrawal signs and symptoms, and which was treated 
with clonidine (0.2 mg three times daily) and methadone 
(30 mg daily that was increased gradually to a maximum 
of 60 mg/day The patient improved gradually and the 
gastrointestinal and respiratory signs and symptoms 
resolved. He was advised to continue taking clonidine 
and methadone for 3-4 weeks, after which he will be 
reevaluated for possible changes. 
 
Comment on patient 5. Withdrawal syndrome is a 
conglomerate of physical and behavioral signs and 
symptoms after the discontinuation or decreasing the 
dose of an opioid or other addictive drug. The severity 
of the symptoms depends on the drug in question and its 
dosage. These include yawning, sweating, lacrimation, 
rhinorrhea, anxiety, irritability, restlessness, insomnia, 
dilated pupils, piloerection, chills, tachycardia, 
hypertension, nausea/vomiting, cramping abdominal 
pains, diarrhea, and muscle aches and pains. 
The incidence and management of withdrawal in 
SCD have not been well studied. It is often confused 
with acute or chronic pain, infection, or other 
comorbidities. It is a cause for hospital readmission 
within one-two weeks after discharge.58 
 Treatment of severe opioid withdrawal includes 
methadone plus clonidine either orally (0.1- 0.2 mg 
every 4-6 hours prn or by using transdermal clonidine 
patch 0.1 mg daily. Other drugs that may be used to treat 
withdrawal include buprenorphine plus naloxone 
orally.59,60  Recently, the FDA approved oral lofexidine 
to treat the symptoms of withdrawal.61 Lofexidine is a 
structural analog of clonidine. Clinical trials comparing 
the two medications showed comparable efficacy, 
though the severity of adverse events was less than those 
with clonidine. This decreased risk for adverse effects 
could potentially make lofexidine a safer option for 
detoxification.62-64 
 
Persistent Sickle Cell Pain. The word "chronic" in 
SCD is problematic and subject to different explanations. 
Thus, SCD itself is a chronic disease that is usually 
symptomatic from childhood through adulthood.  
Table 3. Emergency Room Data for Patient 1 – 5. 
Patient Crisis Day Pain Site Location Pain Score Hospital Admission 
Patient 1 
1 Chest 10 Yes 
33 
Right Thigh 
Right Knee 
Right Leg 
10 No 
75 
Upper Arms 
Elbows 
Forearms 
Wrists 
Hands 
Fingers 
10 No 
114 Lower Back Hip 10 No 
Patient 2 
1 Left Side Chest 10 No 
50 
Thighs 
Legs 
Upper Back 
Lower Back 
Neck 
10 No 
76 Right Shoulder 10 No 
Patient 3 
1 Chest 9 No 
37 Right Foot 8.5 No 
76 Abdomen 8.0 No 
Patient 4 
1 Chest Not Given Yes 
60 Legs Not Given Yes 
87 Abdomen Not Given Yes 
Patient 5 
1 Knees 7 No 
33 Lower Back 8 No 
54 
Arms 
Forearms 
Shoulders 
Not Given Yes 
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Typically, SCD pain is either acute, which is the 
hallmark of the disease or chronic. The latter includes 
such complications as leg ulcers, AVN of humeral or 
femoral heads, and bone infarcts.65-67 
These chronic pain syndromes are localized and last 
for months or years. Recently chronic pain in SCD has 
been defined as ongoing pain that is present in at least 
50% of days over 3 or 6 months in a single or multiple 
locations.6,68 The problem with this definition is that 
during the period of 3- or 6-months, patients with SCD 
may have been treated for acute pain in the ED or 
hospital, thus confounding this definition. Another 
definition of chronic pain that was initially introduced 
by surgeons is acute pain that becomes chronic. This 
definition applies well to post-operative pain that is 
acute after surgery but, in some patients, continues in the 
same operative field for months or years.69 
Actually, this definition applies to the chronic 
complications of SCD. Thus, AVN of the hips may start 
acutely but persists for months or years in the same 
location. A new definition of chronic pain in SCD is the 
pain that persists or occurs between VOCs, the so-called 
chronic on acute pain.70  Although this may occur in 
disorders other than SCD, it is not typical of SCD 
because the sickle pain between VOCs is not the same: 
it varies in location, severity, and outcome, as shown in 
Table 3. Other patients with chronic pain syndromes 
such as fibromyalgia, osteoarthritis, rheumatoid arthritis, 
low back pain, migraine, etc. are rarely treated in the ED 
and rarely require hospital admissions.  Sickle cell 
disease and sickle cell pain are unique and should be 
considered as such. 
Patients discharged from the hospital after treatment 
of uncomplicated VOCs may have: 
1. No pain. 
2. Resolving mild pain as the VOC continues to resolve 
gradually. 
3. Persistent pain after discharge that requires 
continued therapy with oral analgesics, (due to 
tolerance, OIH or withdrawal). 
4. Relapsing pain that occurs after a period with no pain 
(new mild VOC) 
I consider the pain that occurs between VOCs is most 
likely due to tolerance to opioids, withdrawal syndrome, 
OIH, resolving, or acute relapsing pain. These are 
specific diagnoses that have specific recommended 
treatments rather than treating them as chronic pain. 
Accordingly, it seems the use of 
Buprenorphine/Naloxone is potentially a good 
candidate to treat these syndromes as recently reported 
by Osunkwo et al.71 
 
Summary. The acute painful VOC is a unique and 
hallmark clinical entity of SCD. Recurrent VOCs are not 
identical but usually vary considerably among patients 
and longitudinally in the same patient. This is unlike 
chronic pain that tends to be essentially the same from 
time to time.  The pain between VOCs could be due to 
tolerance, OIH, withdrawal, resolving, or relapsing 
VOC.
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